GSK-LSD1 is also tranylcypromine-based and is classified as a catalytic inhibitor of LSD1; however, recent work finds its anti-cancer effect is primarily due to allosteric disruption of the LSD1 interaction with AML oncoprotein Growth Factor Independent 1B (GFI1B) (38). This evidence concerns the gene KDM1A and acute myeloid leukemia.